John D. Zehren

Direttore/Membro del Consiglio presso Singlepass, Inc.

Health Technology

Consumer Services

Profilo

John D.
Zehren is an Independent Director at Singlepass, Inc. since 2022.
Previously, he was the Chief Commercial Officer at Endologix LLC from 2019 to 2020.
He completed his undergraduate degree at the University of St. Thomas.

Posizioni attive di John D. Zehren

Società	Posizione	Inizio
Singlepass, Inc. Singlepass, Inc. Medical SpecialtiesHealth Technology Singlepass, Inc. has developed a unique electrocautery device that improves the clinical outcomes of deep tissue biopsy procedures. The company is based in Lake Forest, CA. The patented, single-use device prevents and stops bleeding caused by tissue extraction by cauterizing the tissue channel. It is the only cautery device of its kind that can be used for biopsy procedures. Singlepass was founded by Peter Sunenshine and Kevin Hirsch. The CEO is Bill Colone.	Direttore/Membro del Consiglio	18/03/2022

Tutte le posizioni attive di John D. Zehren

Precedenti posizioni note di John D. Zehren

Società	Posizione	Fine
ENDOLOGIX, INC.	Corporate Officer/Principal	14/04/2020

Vedi nel dettaglio l'esperienza di John D. Zehren

Formazione di John D. Zehren

University of St. Thomas

Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di John D. Zehren

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Aziende private	2
Endologix LLC Endologix LLC Medical SpecialtiesHealth Technology Endologix LLC engages in the research, development, manufacture, and trade of medical devices for the treatment of aortic disorders such as abdominal aortic aneurysms (AAA). Its products include AFX Endovascular AAA System, Nellix and Ovation. The company was founded in March 1992 and is headquartered in Irvine, CA.	Health Technology
Singlepass, Inc. Singlepass, Inc. Medical SpecialtiesHealth Technology Singlepass, Inc. has developed a unique electrocautery device that improves the clinical outcomes of deep tissue biopsy procedures. The company is based in Lake Forest, CA. The patented, single-use device prevents and stops bleeding caused by tissue extraction by cauterizing the tissue channel. It is the only cautery device of its kind that can be used for biopsy procedures. Singlepass was founded by Peter Sunenshine and Kevin Hirsch. The CEO is Bill Colone.	Health Technology